<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383603</url>
  </required_header>
  <id_info>
    <org_study_id>RES-004</org_study_id>
    <nct_id>NCT01383603</nct_id>
  </id_info>
  <brief_title>Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis</brief_title>
  <official_title>Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with
      allergic rhinoconjunctivitis. Cat-PAD is a novel, synthetic, allergen derived peptide
      desensitising vaccine currently being developed for treatment of cat allergy.

      At present, the efficacy of immunotherapy (peptide or otherwise) can only be established at
      the conclusion of therapy. No reliable predictive biomarkers of clinical efficacy currently
      exist. Identification of surrogate biomarkers of clinical efficacy, would facilitate clinical
      development of peptide immunotherapy vaccines, in addition to providing an improved
      understanding of the underlying molecular mechanisms of efficacy, thus providing new leads
      for therapeutic intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of a change in gene expression over the course of and potentially attributable to Cat-PAD treatment.</measure>
    <time_frame>6 months following treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores for ocular and nasal symptoms</measure>
    <time_frame>4 weeks following treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin production and eosinophil level changes</measure>
    <time_frame>4 weeks following treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional genomic changes</measure>
    <time_frame>4 weeks following treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urine metabolomic profiles</measure>
    <time_frame>4 weeks following treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cat Allergy</condition>
  <arm_group>
    <arm_group_label>Cat-PAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cat-PAD</intervention_name>
    <description>Intradermal injection 1 x 4 administrations 4 weeks apart</description>
    <arm_group_label>Cat-PAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years.

          -  Weight &gt;50 kg.

          -  A minimum 1-year documented history of rhinoconjunctivitis on exposure to cats.

          -  Positive skin prick test to cat allergen.

          -  Subjects must have regular exposure to a cat in their normal living or working
             circumstances throughout the course of the study.

          -  Minimum qualifying rhinoconjunctivitis symptom scores

        Exclusion Criteria:

          -  History of asthma

          -  History of anaphylaxis to cat allergen

          -  History of allergen immunotherapy in the previous 10 years, or in the previous 3 years
             for pre-seasonal immunotherapy treatments

          -  History of any significant disease or disorder (e.g. autoimmune, cardiovascular,
             pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine,
             metabolic, neoplastic/malignant, psychiatric, major physical impairment, severe atopic
             dermatitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L9C3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cat Allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cat-PAD</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

